Daiwa Securities Group Inc. acquired a new position in bluebird bio, Inc. (NASDAQ:BLUE) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 16,895 shares of the biotechnology company’s stock, valued at approximately $1,775,000.
Other hedge funds have also recently bought and sold shares of the company. Pictet Asset Management Ltd. increased its stake in bluebird bio by 26.2% in the first quarter. Pictet Asset Management Ltd. now owns 182,841 shares of the biotechnology company’s stock worth $16,620,000 after buying an additional 37,925 shares in the last quarter. Bank of New York Mellon Corp increased its stake in bluebird bio by 10.7% in the first quarter. Bank of New York Mellon Corp now owns 228,663 shares of the biotechnology company’s stock worth $20,787,000 after buying an additional 22,011 shares in the last quarter. Advisors Asset Management Inc. purchased a new stake in bluebird bio during the first quarter worth approximately $858,000. Commerzbank Aktiengesellschaft FI purchased a new stake in bluebird bio during the first quarter worth approximately $588,000. Finally, Usca Ria LLC purchased a new stake in bluebird bio during the first quarter worth approximately $707,000.
Shares of bluebird bio, Inc. (BLUE) traded down 0.86% during mid-day trading on Friday, reaching $92.45. The company had a trading volume of 497,130 shares. bluebird bio, Inc. has a 12 month low of $37.05 and a 12 month high of $123.75. The company’s market capitalization is $4.21 billion. The firm’s 50-day moving average is $96.49 and its 200 day moving average is $91.07.
bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) EPS for the quarter, missing analysts’ consensus estimates of ($1.66) by $0.07. bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The business had revenue of $16.70 million for the quarter, compared to the consensus estimate of $6.29 million. During the same quarter in the previous year, the business posted ($1.59) EPS. The company’s revenue for the quarter was up 977.4% on a year-over-year basis. On average, equities research analysts predict that bluebird bio, Inc. will post ($6.78) earnings per share for the current year.
A number of research firms have recently commented on BLUE. Wedbush reissued an “outperform” rating and issued a $100.00 price objective (down previously from $121.00) on shares of bluebird bio in a research note on Friday, June 23rd. BidaskClub raised bluebird bio from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 23rd. Morgan Stanley reaffirmed an “equal weight” rating and set a $105.00 target price (up from $91.00) on shares of bluebird bio in a research report on Wednesday, June 14th. Cowen and Company reaffirmed a “buy” rating on shares of bluebird bio in a research report on Friday, June 23rd. Finally, Cantor Fitzgerald set a $39.00 target price on bluebird bio and gave the stock a “sell” rating in a research report on Saturday, June 24th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $100.74.
In other news, Director James Mandell sold 1,000 shares of the business’s stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $95.95, for a total transaction of $95,950.00. Following the completion of the sale, the director now owns 1,000 shares in the company, valued at $95,950. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Daniel Lynch sold 2,500 shares of the business’s stock in a transaction that occurred on Tuesday, June 20th. The stock was sold at an average price of $120.03, for a total value of $300,075.00. Following the sale, the director now owns 5,300 shares of the company’s stock, valued at approximately $636,159. The disclosure for this sale can be found here. Insiders have sold 80,106 shares of company stock valued at $8,308,358 in the last quarter. 3.90% of the stock is currently owned by corporate insiders.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
What are top analysts saying about bluebird bio Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for bluebird bio Inc. and related companies.